Combination therapy with amphotericin B lipid complex and caspofungin acetate of disseminated zygomycosis in diabetic ketoacidotic mice.

Abstract

We studied the combination of amphotericin B lipid complex (ABLC) and caspofungin in mice with disseminated Rhizopus oryzae. Combination therapy improved survival compared to that of mice given monotherapy and that of untreated controls (P < 0.05) but did not improve organ clearance. In addition, prophylactic combination therapy was not more effective than prophylactic ABLC alone.

• Authors: Brad Spellberg, Yue Fu, John E Edwards Jr, Ashraf S Ibrahim
• Journal: Antimicrobial agents and chemotherapy (Antimicrob Agents Chemother) Vol. 49 Issue 2 Pg. 830-2 (Feb 2005) ISSN: 0066-4804 [Print] United States
• PMID: 15673781 (Publication Type: Journal Article)

Chemical References

• Antifungal Agents
• Drug Combinations
• Echinocandins
• Lipopeptides
• Peptides, Cyclic
• Phosphatidylcholines
• Phosphatidylglycerols
• liposomal amphotericin B
• Amphotericin B
• Caspofungin

Topics

• Amphotericin B (therapeutic use)
• Animals
• Antifungal Agents (therapeutic use)
• Caspofungin
• Diabetes Mellitus, Experimental (microbiology, pathology)
• Diabetic Ketoacidosis (complications, metabolism)
• Drug Combinations
• Echinocandins
• Lipopeptides
• Male
• Mice
• Mice, Inbred BALB C
• Mucormycosis (drug therapy, microbiology, mortality)
• Peptides, Cyclic (therapeutic use)
• Phosphatidylcholines (therapeutic use)
• Phosphatidylglycerols (therapeutic use)
• Rhizopus
• Survival